Phacilitate Leaders World


Vanessa Lucey

Vanessa Lucey

Associate Director, CRI Venture Fund & Clinical Accelerator, Cancer Research Institute

Vanessa Lucey is the Associate Director of the Anna Maria-Kellen Clinical Accelerator and Venture Fund at the Cancer Research Institute (CRI’s), New York, NY. The Anna-Maria Kellen Clinical Accelerator, the clinical arm of CRI, is a unique academia-nonprofit-industry collaboration model that serves as an “incubator” to accelerate clinical trials of promising new immunotherapy combinations. At CRI, Vanessa developed CRI’s first-of-its-kind the global immuno-oncology (IO) database to track the landscape from discovery to clinic that was recently published in the Annals of Oncology.

Vanessa has over 15 years’ experience in tumor immunology; she received her Ph.D. from Albert Einstein College of Medicine, her postdoctoral fellowship at NYU School of Medicine, where she has authored or co-authored 27 publications. Vanessa also received her M.B.A from Mercy College School of Business.

  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Anne-Virginie Eggimann
    bluebird bio
  • Great program, great people, great venue.
    Klaus Kühlcke
  • Dynamic, interesting and highly interactive event that promotes exchange and networking in highly specialized field of gene therapy.
    Nathalie Clement
    Powell Gene Therapy Center, University of Florida
  • Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field.
    Dr James Trager
  • It was all business. I’ve never been to an event where over 80% of the conversations I had were constructive to my business objectives.
    Kurt Gielen
    Chemelot Campus B.V.
  • Great way to expand network with global experts in cell and gene therapy who are facing similar challenges.
    Steven Goodman